ストックスクリーナーアプリを入手
4.97
2.05%
0.10
アフターアワーズ：
4.93
-0.04
-0.80%
前日終値:
$4.87
開ける：
$4.85
24時間の取引高:
465.63K
Relative Volume:
0.72
時価総額：
$312.47M
収益：
-
当期純損益:
$-130.41M
株価収益率:
-2.2188
EPS:
-2.24
ネットキャッシュフロー:
$-67.76M
1週間 パフォーマンス:
+10.20%
1か月 パフォーマンス:
-0.80%
6か月 パフォーマンス:
-23.83%
1年 パフォーマンス:
+36.54%
1日の値動き範囲:
$4.73
$5.13
1週間の範囲:
$4.42
$5.13
52週間の値動き範囲:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
名前
Monte Rosa Therapeutics Inc
セクター
電話
617-949-2643
住所
321 HARRISON AVENUE, BOSTON
GLUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.97 | 312.47M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 開始されました | UBS | Buy |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
すべてを表示
Monte Rosa Therapeutics Inc (GLUE) 最新ニュース
Monte Rosa gets FDA clearance to begin testing MRT-8102 - MSN
FMR LLC Reduces Stake in Monte Rosa Therapeutics Inc. - GuruFocus
Bank of America Corp DE Reduces Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions - BioWorld MedTech
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Monte Rosa advances novel inflammatory disease treatment By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102 - marketscreener.com
Monte Rosa Therapeutics, Inc. Announces FDA Clearance of IND Application for MRT-8102, A NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - MarketScreener
Monte Rosa Therapeutics (GLUE) Gains as FDA Clears New Drug Tria - GuruFocus
Monte Rosa gets FDA clearance to begin testing MRT-8102 (GLUE) - Seeking Alpha
Monte Rosa Therapeutics (GLUE) Gains FDA Approval for MRT-8102 I - GuruFocus
Monte Rosa advances novel inflammatory disease treatment - Investing.com
Monte Rosa Therapeutics Announces FDA Clearance Of Ind Application For Mrt-8102 - MarketScreener
Monte Rosa Therapeutics Announces FDA Clearance of IND - GlobeNewswire
FDA Clearance: Monte Rosa's Revolutionary NEK7 Drug Could Transform Inflammatory Disease Treatment - Stock Titan
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet - sharewise
Two Sigma Advisers LP Takes $180,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Sold by Jane Street Group LLC - Defense World
Squarepoint Ops LLC Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
6,231 Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Acquired by BNP Paribas Financial Markets - Defense World
ProShare Advisors LLC Buys New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Deutsche Bank AG Buys 6,633 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Two Sigma Investments LP - Defense World
CDK2 degradation inducers disclosed in Monte Rosa patent - BioWorld MedTech
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Monte Rosa CEO Reveals Latest Molecular Glue Degrader Progress at Major Healthcare Conference - Stock Titan
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
D. E. Shaw & Co. Inc. Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World
Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive - simplywall.st
Dimensional Fund Advisors LP Has $1.01 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Increased by Tower Research Capital LLC TRC - Defense World
Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
Monte Rosa Therapeutics Inc (GLUE)’s Day in Review: Closing at 4.22, Up by 9.61 - DWinneX
Monte Rosa Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Raises Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Monte Rosa Therapeutics Reports Strong Q1 2025 Results - MSN
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - MSN
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq
Monte Rosa Therapeutics (GLUE) Advances Novel Therapeutic Progra - GuruFocus
Monte Rosa Therapeutics, Inc. SEC 10-Q Report - TradingView
Invesco Ltd. Purchases New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Inc (GLUE) 財務データ
収益
当期純利益
現金流量
EPS
Monte Rosa Therapeutics Inc (GLUE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
1.08%
2.14%
大文字化:
|
ボリューム (24 時間):